ArticleThe European respiratory journal2020
JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk.
Article in The European respiratory journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- JAK inhibitors and COVID-19.Journal for immunotherapy of cancer · 2022Pooled it
- Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis.Frontiers in medicine · 2022Pooled it
- Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19.Clinical and translational science · 2021Trial
- Autoimmune hepatitis under the COVID-19 veil: an analysis of the nature of potential associations.Frontiers in immunology · 2025Review
- Epigenetic perspectives associated with COVID-19 infection and related cytokine storm: an updated review.Infection · 2023Review
- An overview on the treatments and prevention against COVID-19.Virology journal · 2023Review
- IFN-American journal of respiratory cell and molecular biology · 2023Article
- COVID-19 and the antiphospholipid syndrome.Autoimmunity reviews · 2022Review
- Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiology.American journal of physiology. Cell physiology · 2022Review
- JAK inhibition as a new treatment strategy for patients with COVID-19.Biochemical pharmacology · 2022Review
- The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges.Thrombosis update · 2022Review
- d-Dimer trend in a long-term rheumatoid arthritis patient with tofacitinib treatment and recent COVID-19 infection.Revista colombiana de reumatologia · 2022Article
- Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.Platelets · 2022Article
- Challenges posed by COVID-19 in cancer patients: A narrative review.Cancer medicine · 2022Review
- Review
- A multi-reference poly-conformational method forPeerJ · 2022Article
- The intersection of COVID-19 and autoimmunity.The Journal of clinical investigation · 2021Review
- Interaction of the inflammatory response and megakaryocytes in COVID-19 infection.Experimental hematology · 2021Review
- Article
- Anti-SARS-CoV-2 Strategies and the Potential Role of miRNA in the Assessment of COVID-19 Morbidity, Recurrence, and Therapy.International journal of molecular sciences · 2021Review
Corrections and comments
- Comment on
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.